Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
多瑞医药
301075
5
诚达药业
301201
(FY)2024/12/31 | (Q9)2024/09/30 | (Q6)2024/06/30 | (Q3)2024/03/31 | (FY)2023/12/31 | (Q9)2023/09/30 | (Q6)2023/06/30 | (Q3)2023/03/31 | (FY)2022/12/31 | (Q9)2022/09/30 | |
---|---|---|---|---|---|---|---|---|---|---|
营业总收入 | 24.65%10.17亿 | 26.39%7.52亿 | 27.85%4.62亿 | 37.60%2.15亿 | 34.97%8.16亿 | 28.04%5.95亿 | 40.51%3.61亿 | 21.90%1.56亿 | -3.55%6.05亿 | 18.65%4.65亿 |
营业收入 | 24.65%10.17亿 | 26.39%7.52亿 | 27.85%4.62亿 | 37.60%2.15亿 | 34.97%8.16亿 | 28.04%5.95亿 | 40.51%3.61亿 | 21.90%1.56亿 | -3.55%6.05亿 | 18.65%4.65亿 |
其他业务收入 | -33.74%1,842.46万 | ---- | -57.37%892.52万 | ---- | 0.36%2,780.56万 | ---- | -6.94%2,093.46万 | ---- | 49.44%2,770.47万 | ---- |
营业总成本 | 21.04%8.76亿 | 22.14%6.44亿 | 19.00%3.97亿 | 24.95%1.88亿 | 21.30%7.24亿 | 20.75%5.27亿 | 32.95%3.34亿 | 17.46%1.51亿 | 7.77%5.96亿 | 27.89%4.37亿 |
营业成本 | 22.10%7.13亿 | 24.81%5.22亿 | 24.24%3.24亿 | 29.41%1.52亿 | 25.95%5.84亿 | 20.76%4.18亿 | 30.51%2.61亿 | 15.04%1.17亿 | 2.20%4.63亿 | 25.07%3.47亿 |
营业税金及附加 | -2.71%754.31万 | -6.83%633.02万 | -29.32%337.4万 | -23.00%200.62万 | 107.37%775.31万 | 145.00%679.4万 | 219.13%477.39万 | 225.49%260.56万 | 62.12%373.88万 | 64.93%277.3万 |
销售费用 | 28.53%5,516.78万 | 27.09%4,100.9万 | 15.68%2,206.96万 | 11.13%1,065.37万 | 30.11%4,292.16万 | 56.89%3,226.89万 | 66.10%1,907.81万 | 53.05%958.65万 | 9.93%3,298.95万 | 28.77%2,056.79万 |
管理费用 | 20.09%5,623.21万 | 23.19%4,214.9万 | 20.44%2,766.96万 | 29.62%1,360.95万 | -1.61%4,682.41万 | 2.11%3,421.38万 | 2.53%2,297.32万 | -16.45%1,049.94万 | 23.38%4,759.11万 | 13.21%3,350.66万 |
财务费用 | -14.17%1,292.67万 | -41.79%760.21万 | -45.52%571.59万 | -11.24%261.38万 | -39.28%1,506.13万 | -25.16%1,306.06万 | 10.57%1,049.24万 | -4.53%294.49万 | 107.67%2,480.34万 | 133.96%1,745.1万 |
-利息费用 | -21.02%753.12万 | -26.13%556.84万 | -29.23%374.41万 | 9.97%194.29万 | -7.76%953.53万 | -2.54%753.85万 | 1.95%529.02万 | -31.83%176.67万 | -25.45%1,033.78万 | -25.24%773.46万 |
-利息收入 | -264.71%-309.03万 | -236.20%-230.07万 | -271.16%-136.76万 | 26.85%-13.83万 | -283.82%-84.73万 | -403.04%-68.43万 | -412.23%-36.85万 | -291.68%-18.9万 | 23.86%-22.08万 | 36.30%-13.6万 |
研发费用 | 14.58%3,132.25万 | 9.51%2,455.05万 | -8.13%1,446.38万 | -2.34%747.35万 | 14.08%2,733.76万 | 41.89%2,241.94万 | 145.77%1,574.36万 | 117.26%765.29万 | 38.93%2,396.41万 | 64.03%1,580.05万 |
信用减值损失 | 8.08%-1,108.65万 | 26.13%-1,159.46万 | -9.28%-964.35万 | -2,070.14%-312.52万 | 54.79%-1,206.11万 | -136.60%-1,569.57万 | -176.93%-882.45万 | -86.61%15.86万 | -190.27%-2,667.96万 | -338.63%-663.38万 |
资产减值损失 | -164.13%-2,979.49万 | ---1,135.46万 | ---969.74万 | ---- | 79.44%-1,128.05万 | ---- | ---- | ---- | -424.72%-5,486.85万 | ---- |
非经营性净收益 | -74.23%-3,994.24万 | -46.25%-2,187.83万 | -138.70%-1,834.56万 | -840.17%-274.51万 | 71.06%-2,292.5万 | -191.14%-1,495.98万 | -274.10%-768.55万 | -80.12%37.09万 | -354.48%-7,921.39万 | -1,641.01%-513.84万 |
公允价值变动净收益 | ---- | ---- | ---- | --4,421.61 | ---- | ---- | ---- | ---- | ---- | ---- |
投资净收益 | 115.76%12.96万 | 160.11%21.75万 | -74.17%14.24万 | --3.53万 | -1,975.81%-82.23万 | -947.06%-36.18万 | 1,778.45%55.13万 | ---- | --4.38万 | --4.27万 |
-其中:对联营合营企业的投资收益 | ---10.51万 | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
资产处置收益 | ---- | ---- | ---- | ---- | -38.47%29.58万 | --29.58万 | --1,944.06 | --1,944.06 | 4,246.00%48.08万 | ---- |
其他收益 | -14.17%80.94万 | 6.43%85.34万 | 45.62%85.3万 | 61.86%34.04万 | -47.88%94.3万 | -44.81%80.18万 | -46.89%58.58万 | -67.75%21.03万 | -18.02%180.95万 | -20.97%145.27万 |
营业利润 | 45.71%1.02亿 | 63.23%8,621.96万 | 134.21%4,631.5万 | 297.24%2,418.55万 | 198.53%6,984.47万 | 130.22%5,281.97万 | 397.37%1,977.48万 | 222.03%608.84万 | -226.26%-7,088.6万 | -54.64%2,294.3万 |
加:营业外收入 | 6,222.47%170.58万 | 1,134.03%24.94万 | 415.14%9.67万 | -24.75%843.02 | -96.87%2.7万 | -97.39%2.02万 | -97.56%1.88万 | -82.04%1,120.26 | -85.67%86.06万 | -87.11%77.54万 |
减:营业外支出 | 467.31%429.61万 | 736.58%366.36万 | 1,906.90%312.46万 | -99.89%40.63 | 1.72%75.73万 | -90.28%43.79万 | -96.42%15.57万 | -97.68%3.59万 | -84.31%74.45万 | 4.34%450.43万 |
利润总额 | 43.50%9,918.12万 | 58.02%8,280.55万 | 120.43%4,328.71万 | 299.53%2,418.63万 | 197.66%6,911.44万 | 172.73%5,240.2万 | 4,850.17%1,963.79万 | 1,630.33%605.37万 | -223.29%-7,076.99万 | -63.25%1,921.4万 |
减:所得税费用 | -15.32%1,452.95万 | 71.24%1,320.17万 | 236.87%728.37万 | 1,278.80%421.01万 | 3,750.67%1,715.75万 | 3,624.76%770.94万 | 186.67%216.22万 | 124.94%30.53万 | -90.84%44.56万 | -103.26%-21.87万 |
净利润 | 62.93%8,465.17万 | 55.74%6,960.37万 | 106.02%3,600.34万 | 247.51%1,997.62万 | 172.96%5,195.69万 | 129.99%4,469.27万 | 504.40%1,747.58万 | 265.16%574.83万 | -235.56%-7,121.55万 | -57.36%1,943.28万 |
持续经营净利润 | 62.93%8,465.17万 | 55.74%6,960.37万 | 106.02%3,600.34万 | 247.51%1,997.62万 | 172.96%5,195.69万 | 129.99%4,469.27万 | 504.40%1,747.58万 | 265.16%574.83万 | -235.56%-7,121.55万 | -57.36%1,943.28万 |
归属于母公司所有者的净利润 | 62.93%8,465.17万 | 55.74%6,960.37万 | 106.02%3,600.34万 | 247.51%1,997.62万 | 172.96%5,195.69万 | 129.99%4,469.27万 | 504.40%1,747.58万 | 265.16%574.83万 | -235.56%-7,121.55万 | -57.36%1,943.28万 |
每股收益 | ||||||||||
基本每股收益 | 65.71%0.58 | 56.67%0.47 | 108.33%0.25 | 250.00%0.14 | 171.43%0.35 | 130.77%0.3 | 500.00%0.12 | 185.71%0.04 | -192.45%-0.49 | -72.92%0.13 |
稀释每股收益 | 65.71%0.58 | 56.67%0.47 | 108.33%0.25 | 250.00%0.14 | 171.43%0.35 | 130.77%0.3 | 500.00%0.12 | 185.71%0.04 | -192.45%-0.49 | -72.92%0.13 |
其他综合收益 | 10.47%118.61万 | -121.69%-41.05万 | -70.04%60.83万 | 102.65%3.73万 | -69.19%107.37万 | -72.41%189.27万 | -31.01%203.08万 | -168.46%-140.87万 | 319.82%348.47万 | 1,364.85%686.01万 |
归属于母公司所有者的其他综合收益总额 | 10.47%118.61万 | -121.69%-41.05万 | -70.04%60.83万 | 102.65%3.73万 | -69.19%107.37万 | -72.41%189.27万 | -31.01%203.08万 | -168.46%-140.87万 | 319.82%348.47万 | 1,364.85%686.01万 |
综合收益总额 | 61.86%8,583.78万 | 48.53%6,919.32万 | 87.69%3,661.17万 | 361.18%2,001.35万 | 178.30%5,303.06万 | 77.18%4,658.53万 | 234.31%1,950.65万 | 313.51%433.96万 | -232.94%-6,773.08万 | -41.61%2,629.28万 |
归属于母公司所有者的综合收益总额 | 61.86%8,583.78万 | 48.53%6,919.32万 | 87.69%3,661.17万 | 361.18%2,001.35万 | 178.30%5,303.06万 | 77.18%4,658.53万 | 234.31%1,950.65万 | 313.51%433.96万 | -232.94%-6,773.08万 | -41.61%2,629.28万 |
货币单位 | 人民币 | 人民币 | 人民币 | 人民币 | 人民币 | 人民币 | 人民币 | 人民币 | 人民币 | 人民币 |
会计准则 | 新会计准则(2007) | 新会计准则(2007) | 新会计准则(2007) | 新会计准则(2007) | 新会计准则(2007) | 新会计准则(2007) | 新会计准则(2007) | 新会计准则(2007) | 新会计准则(2007) | 新会计准则(2007) |
审计意见 | 无保留意见 | -- | -- | -- | 无保留意见 | -- | -- | -- | 无保留意见 | -- |
会计师事务所 | 广东司农会计师事务所(特殊普通合伙) | -- | -- | -- | 广东司农会计师事务所(特殊普通合伙) | -- | -- | -- | 广东司农会计师事务所(特殊普通合伙) | -- |
FY:Financial Year 年度报告,相当于上市公司向SEC披露的10-K文件。
Q:Quarter 季度报告,相当于上市公司向SEC披露的10-Q文件,其中Q1、Q2、Q3、Q4为单季报,跨度为3个月;Q6、Q9为累计季报,Q6为6个月,Q9为9个月。